Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ji Xing In-licenses China Rights to Eye Drop Therapies for Far-Sightedness

publication date: Apr 13, 2022

Shanghai Ji Xing Pharma in-licensed Greater China rights for two eye-drop far-sightedness therapies from San Diego’s Lenz Therapeutics in a $110 million pact. Lenz’s two therapies are based on aceclidine, a small molecule acetylcholine receptor agonist that causes pupil contraction (miosis), creating a pinhole effect that improves near vision. Ji Xing is backed by New York’s RTW Investments, which invested $10 million in Lenz. Ji Xing will pay $15 million upfront and up to $95 million in milestones, plus royalties. Lenz plans to start US Phase III trials of the two presbyopia therapies in H2 of 2020. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here